RB1 and neoplasm: Additionally, in our cases, TP53 mutations were detected in both patients after relapse and, based on the inactivating RB1 mutation and increased CDKN2A expression, the RB1 pathway appeared to be inactivated in the relapsed tumor of case 2, potentially affecting proliferation.